# Key word index


**A**
abdominal: P3.37
abortions: P5.03
ACR criteria: P8.08
acthar gel: P4.20
activated T-cell: P1.06
activity and damage in SLE: P5.38
activity: P5.52, P8.14
adherence: OI6.2, P4.04, P4.11
adipokyne: P5.27
admission: P5.80
adult-onset: OS5.5
adverse event: P4.33, P5.95
ANA: P8.15
anemia: P5.39, P8.06
anifrolumab: P5.11
anti doublestranded DNA: OS8.5
antibiotics: OS5.3
anti-C reactive protein antibody: P5.102
anticoagulation: OI17.2
anti-HMGB1: P2.07, P4.18
anti-mullerian hormone: P5.84
antinuclear antibody: P5.91
anti-nucleosomal antibodies: P2.16
antioxidative response: OS8.1
antiphospholipid antibodies: P2.12, P6.03, P6.05
antiphospholipid syndrome: OI17.2, P6.04, P6.05
antiphospholipid: P6.01
antirheumatic drugs: P5.40
anti-Ro Ab: P5.03
apoptosis: P2.15, P3.08
apoptosis-regulation: P1.06
apoptotic microvesicles: OI24.1
arterial stiffness: P5.51
aseptic necrosis of femoral head: P4.09
atherosclerosis: OS5.2, OS5.7, P3.07, P3.21, P4.08, P5.01, P5.22, P5.26, P5.31, P5.65
auto-antibodies: P2.07, P8.29
autoantibody production: OS7.4
autoantibody: P2.09, P3.11
autoimmune diseases: P3.35, P5.68
autoimmunity pathways: OI1.1
autoimmunity: P3.39, P5.13, P7.09, P8.33
autophagy: OS8.3
autosomal recessive co-segregation with SLE: P7.16
awarness: P5.71

**B**
B cell receptor: OS4.4
B cells: OI16.1, P2.12, P3.06, P4.06, P4.29, P4.35
B lymphocyte stimulator: OS8.4
B lymphocytes: P2.04
B1 cells: P2.03, P2.11
BAFF receptor: P3.17
BAFF: P3.17, P5.103, P5.48
BAFF/BLyS blockade: OS4.5
BANK1: OI7.2
B-cells: P2.13, P2.14
BCL2: P4.23, P4.24
BCR signaling: P2.10, P2.11
BDCA2: OS25.3
belimumab: P4.03, P4.14, P4.28, P4.29, P4.33, P4.34
Biologics: P4.06, P4.29
biomarker: P2.09, P3.20, P3.30, P5.33, P5.85, P7.10, P8.04
BLK: P2.03
bone mineral density: P5.30
breastfeeding: P5.40

**C**
C1qB gene: P7.16
capabilities: P8.26
cardiac disease: P5.29
cardiovascular disease: P5.26, P5.46, P5.51, P5.91
cardiovascular event: OS5.2
cardiovascular risk: OI22.3, P8.23
cardiovascular: P4.32, P5.14
carotid intima-media thickness: P8.31
carotid ultrasound: P5.51
caucasian: P5.48
Cblb: P1.04, P1.05
CD134: P1.08
CD16: P3.19
CD22: OS4.4
CD4+ T cells: P1.01
CD40: OS4.4
CD40L: P2.06
cell cycle: P3.06
cerebrospinal fluid: P3.11
chemokines: P5.33, P8.09
childhood: P7.08
childhood-onset SLE: OI14.2, P5.19, P7.13, P7.06, P7.07
China: P5.37
chronic arthritis: P7.07
chronic daily headache: P5.101
chronic inflammation: OI13.1
chronic kidney disease: P5.54
cistatin C: P5.85
class IV: P5.86
classification criteria: P5.88
classification: P5.50
clinical differences: OS5.6
clinical features: P3.39
clinical practice: P4.14
clinical research: OS15.5
clinical trial: OI9.2, OI28.1, P4.13
cluster analysis: P5.05
coagulation factor XIII: P5.22
cognitive deficit: P5.57
cognitive dysfunction: P6.03
cognitive function: P5.07, P5.08, P5.21, P5.77
cognitive symptoms inventory: P5.56
cohort study: P5.36
cohort: P5.26
common variable immunodeficiency: P7.09
complement activation: P8.17
complement C4: P2.17
complement: P3.34, P5.17
congenital heart block: P7.10
consensus: OS5.1
contact system: P8.10
coronary-artery calcification: OS5.7
corticosteroid: P4.09
CR3: P2.17
cardiovascular: P5.01
curcumin: P4.26
cutaneous lupus erythematosus: P5.97
cyclophosphamide: P5.104, P7.14
cystitis, interstitial: P5.42
cytokines: P1.10, P2.05, P2.15, P3.24, P3.26, P3.27, P5.33, P7.13, P8.09

**D**
damage and organ system involvement: P5.39
damage and organ system involvement: P5.39
damage: OI14.3, P5.05, P5.16, P5.52, P7.04, P8.14
death: P5.16
demographics: P5.11
dendritic cells: OI16.1, P3.13, P3.14
Denmark: P5.106
dental amalgam: P8.28
depomedrol: P4.27
depression: P5.105, P5.41
diagnosis: P3.18
diet: P1.11, P5.58
diffuse alveolar hemorrhage: P5.94
digital vasculitis: P7.06
direct medical costs: P5.89, P5.92
discoid lupus erythematosus: P8.20
discoid: P8.05
disease activity measures: P5.23
disease activity patterns: P5.98
disease activity: OI9.2, P3.21, P3.26, P4.32, P4.37, P5.06, P5.17, P5.28, P5.35, P5.49, P5.82, P7.04, P8.08
disease burden: P5.09
disease duration: P5.09
disease mechanisms: OS8.2
DNA damage: P3.29
DNA methylation: OS7.4, P3.09
dyslipidemia: P5.06

**E**
Early incomplete lupus: P3.32
early systemic lupus erythematous: P5.90
Education: P7.11
Efficacy endpoints: P5.10
efficacy: P4.15
EliA: OS8.5
embryonic stem cells: P4.36
Emergencies: P3.37
endothelial progenitor cells: P4.28
enterocolitis: P5.42
Environment: P1.11
epicutaneus: P3.34
epidemiology: P5.16, P5.24, P5.79
Epigenetics: P3.09, P3.28, P3.36, P8.02
Epstein Bar virus: P7.01
EQ-5D-3L: P5.62
estrogen: P3.02, P3.13
everyday life: OI21.3
evolution of systemic lupus erythematosus: P5.90
Experimental intervention: P3.28
Exposure: OS5.3
expression: P3.15

**F**
family-studies: P3.16
Farr: OS8.5
fecundity: P7.12
fibroblasts: P3.31
fibromyalgia: P5.55
flare characteristics: P5.20
flares: P5.93

flow cytometry: P2.10
fMRI: P5.21
follicular helper T cells: OS8.6, P1.07
free light-chain: P5.49
función Renal: P5.34

**G**
galectin-1: P1.06
gender differences lupus: P5.78
gender: P5.97
gene expression: OS4.5
gene signature: OI20.2
genetics: P3.04, P3.06, P3.16, P8.01
genome wide association study: P8.01
global diffuse proliferative lupus nephritis: P7.15
glomerulonephritis: P5.34, P5.70
glomerulus: P2.05
glucocorticoids: P5.58
granzyme B: P2.14
ground-glass opacification: P5.45

**H**
haplotype: P3.04
headache: P5.53
health resource utilization: P5.89, P5.92
healthcare system: P5.105
health-related quality of life: P5.64
heart rate variability: P3.26
HELLP syndrome: P5.66
hematological disorders: P5.73
hepatitis B /C: P5.99
high triple positive: P6.01
highly effective antiretroviral therapy (HAART): P8.07
histone deacetylase inhibitor: P4.35
HLA genetic variation: OS7.4
HLA region: P3.04
HMGB1: P2.07, P4.18
hospitalization: P5.24, P5.52
human immunodeficiency virus (HIV): P8.07
humanised anti-CD20: P4.05
hydronephrosis: P5.42
hydroxychloroquine: OI6.2, P4.11, P4.21, P4.27, P5.12, P8.23

**I**
iC3b: P5.17
ICOSL: P1.03
IFNalpha: P4.30
IFN-Kinoid: P4.30
IFN-γ-receptor-1: P2.02
IgG antibodies: OI7.2
IL-2: P1.07
IL-21: P1.12, P2.14
imaging: P8.03
immune Complex: OI1.1
immunoChip: P3.16
immunofluorescense: P8.33
immunoglobulin: P4.07
immunomodulation: P4.36
immunosuppressant: P5.02
immunosupressive medications: P5.99
impaired renal function: P5.12
improvement: P5.28
in vitro induced regulatory T cells: P3.01
inception cohort: P5.96
incidence: P5.29
infection: P5.18
inflammation: P3.23, P3.33
inflammatory skin diseases: P3.25
inhibitory Fc receptor: P3.03
innate immunity: P3.02, P3.25
interferon regulatory factor-5: OS8.4, P3.03, P3.07
interferon response: P3.31
interferon signature: P3.10, P8.04
interferon stimulated genes: P3.32
interferon: OI20.2, P2.08, P3.15
interleukin 6: P3.38
interstitial infiltrate: P5.86
interstitial lung disease: P5.61
intimae-media thickness: P8.21
iTRAQ technology: P7.17

**J**
Jessner lymphocytic infiltration of the skin: P8.22
joint count: P4.20
joint involvement: P5.35
juvenile SLE: P7.04
juvenile systemic lupus erythematosus (JSLE): OI14.3, P7.14, P7.18
juvenile: OS5.6
juvenile-onset: OS5.5

**K**
ki-67: P8.13
Kikuchi's syndrome: P8.25

**L**
lactation: P5.40, P8.30
LILRA4: P3.12
long term damage: P7.12
long term outcomes: P7.11
long-term corticosteroid treatment: P8.31
LSQ: P4.02
lupus disease activity: P8.04
lupus erythematosus systemic: P3.38, P5.44, P8.11
lupus erythematosus: P8.22
lupus groups: P8.26
lupus like glomerular disease: P8.07
lupus nephritis (LN): P7.17
lupus nephritis outcomes: P5.86
lupus nephritis: OI24.1, P1.12, P2.04, P2.12, P2.13, P3.09, P3.19, P4.35, P5.02, P5.103, P5.34, P5.44, P5.54, P5.75, P5.85, P5.89, P8.10, P8.13, P8.24, P8.33
lupus: OI28.1, OI6.2, OI9.2, OS4.5, P1.07, P3.07, P3.14, P3.15, P3.18, P3.24, P3.34, P4.23, P4.24, P5.07, P5.08, P5.100, P5.104, P5.18, P5.22, P5.46, P5.60, P5.71, P5.76, P5.77, P5.80, P5.81, P5.83, P7.08, P8.09, P8.14, P8.28
lupus-associated atherosclerosis: P1.01
lupus QoL: P8.32
lymphadenopathy: P4.26
lymphocytes: P3.30
lymphopenia: P4.22, P5.38

**M**
macrophages: P3.27
macrophagic activation: P8.25
magnetic resonance imaging: P5.25, P6.03
male SLE: P8.16
males: P5.43, P8.29
malignancy: P5.104
management: P5.20
MAPK activation: P3.31
marginal zone-B cells: P2.02
measurement: OS5.4
medication decision-making: P5.100
melanocortin: P4.13
mercury: P8.28
methylation: P8.02
microarray: P3.18, P8.05
microparticles: OS8.2, P8.12
microRNA 146a: P3.36
micro-RNA: OS8.2
microRNA: P3.20, P3.28
minimally important difference: P4.37
MiR155: P2.01
mofetil mycophenolate: P4.31
monoclonal antibody: P4.16
monocyte subsets: P8.12
monocytes: P3.19
mortality: P5.05, P5.79, P5.81, P5.91, P5.94, P7.05
mosaic: P5.87
mouse: P4.08
mrl lpr mice: P4.18
MRL-lpr/lpr mice: P4.26
mTORC inhibitor: P6.04
mucosal-associated invariant T cells: P1.02
multicenter cohort: P7.06, P7.07
multiple autoimmun syndrome: P3.35
murine lupus: P2.02, P3.13
Mx1: P3.10
myelitis: P5.60
myeloperoxidase: P5.31
myocardial Infarction: OS5.2
myocarditis: P5.74

**N**
nephritis: P2.03, P3.23, P3.24, P4.12, P4.15, P4.19, P4.34, P5.19
nervous system: P5.83
neurocognitive deficit: P5.56
neurofilament: P8.18
neurological disorders: P5.53
neuromyelitis optica: P5.60
neurophsychiatric symptoms: P3.10
neuropsihiatric lupus: P5.67
neuropsychiatric manifestations: P7.18
neuropsychiatric SLE: P3.11
neuropsychiatric systemic lupus erythematosus: P5.72
neuropsychiatric: P5.25, P7.08
neutrophil extracellular traps: OI24.1, P2.04, P3.27, P8.10
new criteria: P8.08
N-methyl-D-aspartate receptor: P5.04
nominal group technique: P5.100
non-scarring alopecia: P8.27
novel therapy: P4.16
NPSLE: OI14.2, P5.04
NR1: P5.04
nucleic acid: P2.17
nutrition: P5.65
NZB x NZW F1 lupus-prone mice: P4.36
NZBWF1 Mice: P4.23, P4.24

**O**
observational: P4.03
omics: P5.13
onset: P5.59
organ damage: P4.01, P4.17, P5.41, P5.96
osteoporosis: P5.32, P5.106
outcome: OI14.3, P5.36, P7.03, P7.15
ovarian reserve: P5.84
overweight: P5.46

oxidative burst: OS8.1
oxidative stress: P1.11

**P**
P140 peptide: OS8.3
p27: P1.05
patient considerations: OS15.5
patient involvement: P8.26
patient reported outcomes: P4.37, P5.23, P5.47
patient: P4.04
patient-perceptions: P5.20
pediatric lupus: P7.05
pediatric systemic lupus erythematosus: P7.01
peptidylarginine deiminase type 4: P8.11
perceived stress: P5.41
percutaneous renal biopsy: P8.24
pericarditis: P5.74
peripheral nervous system: P5.15
phagocytosis: P2.15, P3.08
phase III: OI28.1
physical exercise: P5.27
piHDL: P5.31
PIL: P2.01
plasma cells: OS8.4
plasmacytoid dendritic cells (pDC): OI20.2, OS25.3, P1.01, P3.30, P4.16
PML: P4.22
polineuropathy: P5.53
polymorphism: P3.12
post-processing techniques: P5.45
PPAR: P4.08
pre-clinical: P8.15
predictive factor: P5.67
prednisone: OI22.3, P3.17
pregnancy: P4.21, P5.44, P5.66, P5.71
pregnant SLE patients: P5.03
pre-menopausal women: P5.32
preterm birth: P4.21
prevalence: P5.24
prevention: P4.09
primary Sjögren's syndrome: P2.06
pristane: P2.01
prognosis: P8.16
programmed death-1: P1.02
proinflammatory Th lymphocytes: OI13.1
proliferative: P4.19
promoter methylation: P3.36
prospective study: P5.96
protein kinase C delta: P7.09
protein S: P3.21
proteinuria: OS5.4, P2.05
proteomic: P7.17
proton magnetic resonance spectroscopy: P5.101
PUFA: P3.33
pulmonary arterial hypertension: P5.36, P5.61
pulmonary hemorrhage: P5.94, P7.03
pulmonary vasculitis: P5.45

**Q**
qualitative study: OI21.3
quality of life: P5.09, P5.62, P7.12, P8.32
questionnaire: P4.02

**R**
REAL: P5.82
recent onset systemic lupus erythematosus: P5.90
reclassification: P5.13
reduced organ involvement: P3.01
refractory lupus: P7.02
regional variations: P5.10
regulatory B-cells: P2.13
regulatory T cells: P1.05
remission: OS5.1, P4.12
renal biopsy complications: P8.24
renal biopsy: P8.13
renal survival: P4.31
renal transplantation: P6.04
repository corticotropin: P4.25
response: P4.05
responsiveness: P8.32
rheumatoid arthritis: P5.69
rheumatoid factor: OI1.1
rhupus: P5.69
risk factors: OS5.7, P5.01, P5.93
rituximab: P4.05, P4.06, P4.07, P4.12, P7.02, P7.18

**S**
S100A8/A9: P5.70
satisfaction: P4.02
sCD40L: P3.22
screening: P5.99
SDI: P4.01, P4.17
segmental diffuse proliferative lupus nephritis: P7.15
severe lupus nephritis: P4.31
severity: OS5.6
sex difference: P5.87
sex: P5.97
SF-36v2: P5.62
sifalimumab: P5.10, P5.11
silent atherosclerosis: P8.31
single nucleotide polymorphism: P8.20
skin: P3.23, P8.22
SLE immune complexes: P2.08
SLE: OI21.3, OS5.3, P2.09, P3.12, P3.32, P3.33, P3.35, P4.07, P5.103, P5.21, P5.55, P5.58, P5.63, P5.65, P5.66, P5.70, P5.82, P5.84, P5.98, P6.01, P7.03, P8.16, P8.25
SLE, APS, anti-DNA positivity.: P6.02
SLEDAI: P4.20
SLEDAI-2K: P5.48, P5.49, P7.13
SLICC: P5.88
Smad pathway: P1.09
socioeconomic factors: P5.37
South Asians: P5.14
stabilin-2: P3.08
stochastic sensors: P3.38
stratification: P8.03
stroke: P5.25
subacute cutaneous lupus erythematosus: P5.88, P8.05
subclinical atherosclerosis: P8.21
subcutaneous human immunoglobulin: P4.10
sVCAM-1: P4.25
swollen to tender count ratio: P5.35
systemic lupus erythematosus disease activity Index: P7.01
systemic lupus erythematosus: OS15.5, OS5.5, OS8.6, OS25.3, P1.02, P1.09, P1.10, P1.12, P3.01, P3.02, P3.22, P3.39, P4.01, P4.03, P4.10, P4.11, P4.17, P4.28, P4.33, P4.34, P5.06, P5.101, P5.102, P5.105, P5.106, P5.12, P5.15, P5.27, P5.29, P5.30, P5.32, P5.38, P5.39, P5.43, P5.50, P5.64, P5.68, P5.69, P5.73, P5.74, P5.75, P5.78, P5.79, P5.93, P8.12, P8.17, P8.18, P8.20, P8.21, P8.23, P8.27, P8.29, P8.30
systemic lupus: P4.27, P5.28
systemic's diseases: P3.37

**T**
T cell regulation: OS8.3
T cells: P1.04, P1.08
T follicular helper cells: P1.08
tacrolimus: P4.15
tertiary lymphoid structures: P2.06
TGF-b: P1.09
therapy: P7.02
thrombocytopenia: P8.06
thrombosis: P6.05
thrombotic thrombocytopenic purpura: P3.22, P8.06
tie-2: P8.18
TLR7: OI7.2, P3.03
tolerance: P1.04
toll-like receptors: OI16.1
total hip arthroplasty: P5.95
total knee arthroplasty: P5.95
treatment: P4.04, P4.19
treat-to-target: OS5.1
TWEAK: OS8.6
type I Interferon: P3.29, P8.17
tyrosine kinase: P3.25

**U**
ultrasound: P8.03, P8.15

**V**
vasculitis: P5.76
vitamin D enzymatic machinery: P8.19
vitamin D level: P8.27
vitamin D: P1.10, P5.30, P5.63

**W**
warfarin: OI17.2
WHO classes Lebanon: P5.75
whole exome sequencing (WES): P7.16
work participation: P7.11

**X**
X chromosome: P5.87

**Y**
young age: P5.67